187 filings
Page 5 of 10
6-K
IMAB
I-Mab
19 Oct 21
I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
4:02pm
6-K
IMAB
I-Mab
15 Oct 21
I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China
6:06am
6-K
IMAB
I-Mab
4 Oct 21
I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab
6:09am
SC 13D/A
IMAB
I-Mab
27 Sep 21
I-Mab / HHLR ADVISORS ownership change
4:15pm
6-K
IMAB
I-Mab
31 Aug 21
I-Mab Provides Business and Corporate Updates and Reports Financial
6:42am
6-K
IMAB
I-Mab
20 Aug 21
I-Mab Announces Establishment of Environmental, Social and Governance Committee
4:01pm
6-K
IMAB
I-Mab
12 Aug 21
I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19
7:46am
6-K
IMAB
I-Mab
30 Jul 21
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
7:31am
6-K
IMAB
I-Mab
29 Jul 21
I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million
4:02pm
6-K
IMAB
I-Mab
27 Jul 21
I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of
4:36pm
SC 13G
Fortune Eight Jogging Ltd
19 Jul 21
I-Mab / Fortune Eight Jogging ownership change
6:08am
424B3
IMAB
I-Mab
16 Jul 21
Prospectus supplement
4:01pm
6-K
IMAB
I-Mab
25 Jun 21
I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus
4:01pm
SC 13D/A
IMAB
I-Mab
24 Jun 21
I-Mab / HILLHOUSE CAPITAL ADVISORS ownership change
6:56am
424B3
IMAB
I-Mab
23 Jun 21
Prospectus supplement
4:01pm
SC 13G/A
IMAB
I-Mab
21 Jun 21
I-Mab / Genexine ownership change
11:10am
6-K
IMAB
I-Mab
1 Jun 21
Current report (foreign)
8:07am
S-8
IMAB
I-Mab
28 May 21
Registration of securities for employees
4:01pm
6-K
IMAB
I-Mab
20 May 21
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients
6:10am
424B3
IMAB
I-Mab
30 Apr 21
Prospectus supplement
4:03pm